Naglaa H. Allam

32511, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Hepatitis C Elimination in Egypt: Story of Success.

Hepatitis C Elimination in Egypt: Story of Success.

Journal: Pathogens (Basel, Switzerland)

Published: July 17, 2024

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.

Journal: Drugs of today (Barcelona, Spain : 1998)

Published: March 17, 2021

Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis.

Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis.

Journal: World journal of hepatology

Published: September 19, 2019

Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma.

Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma.

Journal: World journal of hepatology

Published: March 12, 2019

Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.

Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.

Journal: Journal of medical virology

Published: January 11, 2018

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

Journal: Journal of hepatology

Published: June 05, 2017

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

Journal: The lancet. Gastroenterology & hepatology

Published: March 07, 2016

Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.

Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: October 31, 2015

The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.

The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.

Journal: Hepatology international

Published: March 03, 2015

Normal liver stiffness: A study in living donors with normal liver histology.

Normal liver stiffness: A study in living donors with normal liver histology.

Journal: World journal of hepatology

Published: December 20, 2014

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.

Journal: World journal of gastroenterology

Published: December 17, 2014

De novo malignancies after liver transplantation: a single-center experience.

De novo malignancies after liver transplantation: a single-center experience.

Journal: Annals of Saudi medicine

Published: June 19, 2012

Showing 1-12 of 16

Last Updated: 09/26/2026